Piramal Pharma Acquires Majority Stake in Yapan Bio

Editor’s Take: CEO Peter DeYoung has played a major role in transforming Piramal Pharma into a more focused, globally integrated pharmaceutical company. Revisit Contract Pharma’s exclusive interview with DeYoung from 2022.

Piramal Pharma Ltd. (PPL) has acquired an incremental 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based CDMO specializing in vaccines and biologics, for an aggregate cash consideration of $7.95 million. As a result of this transaction, PPL now owns 74% of Yapan Bio’s equity, making Yapan Bio a subsidiary of PPL.

This acquisition marks a step forward in PPL’s long-term plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary’s advanced large molecule capabilities into its integrated service offering, enabling it to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL.

This acquisition also further enhances ADCelerate, PPS’s fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months, and reinforces PPL’s ability to deliver life-saving ADCs to market with speed and consistency.

“This strategic investment doesn’t just fuel our long-term growth; it also puts Patient Centricity into action,” said Peter DeYoung, CEO, Piramal Global Pharma. “By integrating Yapan Bio’s specialized expertise into our global network, we’re empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.